Nasdaq:NEO
NEOGENOMICS INC
A premier genomics technology firm driving precision medicine innovation through proprietary AI platforms and data-driven clinical solutions.
Key Metrics
Investment Thesis
Bull Case
NEO represents a high-potential turnaround story with revenue growing rapidly as its proprietary data platform gains market traction among leading biopharma partners. The company's substantial cash position of $159.6M provides operational runway to execute strategic initiatives while scaling commercial operations toward eventual profitability. Investors may view the significant goodwill and intangible assets as indicators of valuable acquired technologies that could unlock future royalty streams.
Bear Case
The persistent net loss of over $100M annually suggests fundamental business model challenges that have not been resolved despite impressive revenue growth trends. With long-term debt reaching $341.9M and a retained earnings deficit of -$433.8M, the company faces substantial refinancing risks if market conditions deteriorate. The negative free cash flow generation indicates that current operations are not self-sustaining, requiring continuous external capital raises that may dilute shareholders.
About NEOGENOMICS INC
NEO Genomics Inc. is a leading genomics technology company providing data-driven insights and services to accelerate the development of novel diagnostics, therapeutics, and precision medicine solutions. Serving global markets including oncology, neuroscience, and immunology, the company leverages its proprietary AI platforms and extensive clinical trial networks to translate genomic discoveries into actionable healthcare innovations.
Analysis
Management Discussion
Despite a 43% revenue growth from $509.7M in 2022 to $727.3M in 2025, NEO continues to post substantial losses, with net income declining to -$108M in the latest period compared to -$78.7M the prior year. The widening gap between cash flow from operations of just $5.2M and total operating expenses exceeding $430M highlights the capital-intensive nature of scaling genomics infrastructure. Management's heavy investment in research and development of $37.1M and general administration of $273.3M reflects aggressive expansion strategies that have yet to convert into profitability.
Industry Overview
The genomics industry is experiencing rapid transformation driven by advances in artificial intelligence and the increasing demand for precision medicine solutions across oncology and rare diseases. Companies with proprietary datasets and established clinical networks are consolidating market share as regulatory frameworks evolve to support data-driven drug development pipelines. Investors are closely monitoring the transition from R&D-focused models to commercialized product revenues that can generate sustainable cash flows.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $509.7M | $591.6M | $660.6M | $727.3M |
| Cost of Revenue | $321.8M | $347.0M | $370.5M | $413.0M |
| Gross Profit | $187.9M | $244.6M | $290.1M | $314.3M |
| Operating Expenses | $345.5M | $352.3M | $382.2M | $430.2M |
| Operating Income | $-157.6M | $-107.7M | $-92.1M | $-115.9M |
| R&D | $30.3M | $27.3M | $31.2M | $37.1M |
| G&A | $243.4M | $243.1M | $259.7M | $273.3M |
| Marketing | $67.3M | $70.8M | $84.7M | $92.0M |
| Stock-Based Comp | $24.7M | $24.6M | $33.4M | $41.3M |
| Depreciation | $35.4M | $37.5M | $39.1M | $36.1M |
| Amortization | $34.1M | $35.1M | $33.4M | $31.8M |
| Other OpEx | $4.5M | $11.1M | $6.7M | $27.8M |
| Non-Operating Income | $-1.7M | $10.6M | $11.4M | $5.6M |
| Interest Expense | $1.5M | $6.9M | — | — |
| Interest Income | — | — | $18.4M | $9.1M |
| Pre-Tax Income | $-159.3M | $-97.1M | $-80.7M | $-110.3M |
| Income Tax | $-15.1M | $-9.1M | $-1.9M | $-2.2M |
| Continuing Ops | $-144.2M | $-88.0M | $-78.7M | $-108.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-144.2M | $-88.0M | $-78.7M | $-108.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-144.2M | $-88.0M | $-78.7M | $-108.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $605.3M | $596.8M | $596.0M | $376.3M |
| Cash & Equivalents | $263.2M | $342.5M | $367.0M | $159.6M |
| Accounts Receivable | $119.7M | $131.2M | $150.5M | $159.2M |
| Inventory | $24.3M | $24.2M | $26.7M | $28.6M |
| Other Current Assets | $198.1M | $98.9M | $51.7M | $28.9M |
| Long-Term Assets | $1.13B | $1.08B | $1.04B | $983.5M |
| PP&E (Net) | $102.5M | $92.0M | $94.1M | $84.8M |
| Intangibles | $408.3M | $373.1M | $339.7M | $286.5M |
| Goodwill | $522.8M | $522.8M | $522.8M | $524.3M |
| Operating Leases | $96.1M | $91.8M | $79.6M | $78.4M |
| Other LT Assets | $5.1M | $4.7M | $5.9M | $9.4M |
| Total Assets | $1.74B | $1.68B | $1.64B | $1.36B |
| Current Liabilities | $89.9M | $96.3M | $301.2M | $88.3M |
| Accounts Payable | $20.5M | $20.3M | $21.6M | $23.1M |
| Current Debt | — | — | $200.8M | $0 |
| Current Leases | $6.6M | $5.6M | $3.4M | $4.8M |
| Deferred Revenue | $7.6M | $2.1M | $409.0K | $851.0K |
| Other Current Liab | $55.3M | $68.2M | $75.1M | $59.6M |
| Long-Term Liabilities | $652.1M | $643.4M | $434.5M | $435.0M |
| Long-Term Debt | — | — | $340.3M | $341.9M |
| LT Operating Leases | $69.0M | $67.9M | $60.8M | $62.8M |
| Other LT Liab | $583.1M | $575.5M | $32.9M | $29.9M |
| Total Liabilities | $742.0M | $739.7M | $735.7M | $523.3M |
| Shareholders' Equity | $998.0M | $941.5M | $902.3M | $836.6M |
| Retained Earnings | $-159.1M | $-247.1M | $-325.8M | $-433.8M |
| AOCI | $-3.9M | $-1.7M | $-206.0K | $4.0K |
| Total L&E | $1.74B | $1.68B | $1.64B | $1.36B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-144.2M | $-88.0M | $-78.7M | $-108.0M |
| Non-Cash Adjustments | $90.3M | $58.8M | $54.6M | $126.3M |
| Working Capital Changes | $-12.0M | $27.2M | $31.2M | $-13.0M |
| Cash from Operations | $-66.0M | $-2.0M | $7.0M | $5.2M |
| Capital Expenditures | $30.9M | $28.8M | $41.1M | $27.0M |
| Cash from Investing | $517.0K | $76.7M | $12.9M | $-12.3M |
| Cash from Financing | $11.8M | $4.6M | $4.6M | $-200.3M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-53.6M | $79.3M | $24.5M | $-207.4M |
| Beginning Cash | $316.8M | $263.2M | $342.5M | $367.0M |
| Ending Cash | $263.2M | $342.5M | $367.0M | $159.6M |
Frequently Asked Questions
How does NEOGENOMICS INC make money?
The company generates revenue primarily through licensing fees and royalties from its proprietary datasets, contract research services for biopharmaceutical clients, and commercial sales of genomic-based diagnostic products. Additional revenue streams include grants and collaborations focused on advancing cancer immunology and neurodegenerative disease research.
What are the main risks for NEO?
Significant cash burn continues as the company reports a net loss of $108M, raising concerns about long-term capital sustainability without further financing. Heavy reliance on third-party contract research revenue exposes the business to client concentration risks and potential economic downturns affecting pharma spending. Intellectual property protection remains critical given the competitive genomics landscape and potential regulatory shifts in data privacy laws.
What is NEO's competitive advantage?
NEO possesses a unique data moat built on the world's largest collection of annotated genomics datasets, enabling superior AI model training for drug discovery. The company benefits from deep industry partnerships with top-tier academic institutions and major pharmaceutical companies that validate its platform capabilities. Its specialized expertise in translating complex genomic data into clinical applications creates high barriers to entry for competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.